Page 1

Heal. Help. Hope.

2012 Cancer Program Annual Report Based on 2011 Activities at

Affiliated with, but not controlled by, Baylor Health Care System or its subsidiaries or community medical centers


TABLE OF CONTENTS

1

2011 CANCER COMMITTEE MEMBERS

2

CANCER COMMITTEE CHAIRMAN/ MEDICAL DIRECTOR REPORT

3

WISE REGIONAL CANCER COMMITTEE ACTIVITIES AND ACHIEVEMENTS

5

WISE REGIONAL HEALTH FOUNDATION AND MARY’S GIFT

6

NATIONAL CANCER DATABASE CANCER PATIENT PROFILE REPORTS (CP3R)

7

WISE REGIONAL PROGRAM DEVELOPMENT AND INTEGRATION WITH CANCER PROGRAM

9

COMMISSION ON CANCER ACCREDITATION AND CANCER RESOURCE ROOM

10 CANCER REGISTRY REPORT 11

FOCUSED COLON CANCER CANCER FINDINGS REPORT

13

GLOSSARY

2011 Cancer Committee Members Dr. Neelima Maddukuri Medical Oncology, Medical Director and Chair Dr. Greg Garrett Radiation Oncology Dr. Mark Goss Surgical Oncology, ACOS COC Liaison Dr. Joe Barns Pathology Sandy Tate Pharmacy Angela Christian RN, OCN Director of Oncology Carol Poehl, CTR Cancer Registrar Lynn Sherman Quality Management Melanie Belcher American Cancer Society Janis Honeycutt MS, RD, LD Dietary Kelly Rodriguez LBSW Social Worker Dawn Byrd, RHIA Health Information Services Amy Fields Laboratory Laurie Edelman Nursing Cynthia Sanchez Radiation Nurse Treva Grisham LOTA, CLT Inpatient Rehabilitation


CANCER COMMITTEE CHAIRMAN REPORT and underinsured women remains a very successful program. Cardiothoracic surgeons Dr. Tung Cai and Dr. T. Acuff continued to provide excellent standards in the surgical management of lung cancer. Wise Regional Health System and the North Texas Cancer Center celebrated their second annual Cancer Survivor Day in June 2011 at the Decatur Civic Center. It was well attended and was a grand success.

Neelima Maddukuri, M.D.

As

the Cancer Committee Chair of the Wise regional Cancer Program, it is a pleasure to present the 2012 annual report based on 2011 activities. 2011 marked yet another year of growth and maturation for the cancer program at Wise Regional Health System. Full-time medical oncology services continued under my direction and full-time radiation services under the direction of Dr. Guy Garrett and Dr. Gregory Echt. Dr. Mark Goss continued to serve as the Cancer Committee Liaison. The cancer program continued to deliver compassionate, advanced comprehensive cancer care in Wise County. It was the fifth year of activities and data accumulation for the program. The Cancer program was surveyed by the Commission on Cancer of the American College of Surgeons on September 28, 2010 and has been accredited with commendation. Provision of PET scanning, for the first time in Wise County took place in 2011. PET scanning is currently available through a mobile PET scanner once a week in Decatur. Future plans include acquiring a full-time PET scanner.

The cancer program continues its commitment to education through the discussion of difficult oncology cases at the CME accredited interdisciplinary tumor board. Our monthly didactic tumor board conference provides discussion of interesting cases, which is well attended by physicians from multiple specialities and other ancillary staff. In the fall of 2011, the Cancer Program invited Dr. Tung Cai, cardiothoracic surgeon, as the guest speaker for a special educational symposium on the topic of “Current Updates and Trends in the Surgical Management of Lung Cancer.” Various community outreach programs have been successfully organized throughout the year. The Cancer Resource Center, in the Women’s Health Center is staffed by volunteers trained by the American Cancer Society . The facility is equipped with free patient literature as well as wigs, hats, scarves and prosthesis. Patients and families access local patient support groups and programs through the Resource Center. These are dynamic yet challenging times in the field of medicine and oncology. I have complete faith that the cancer program here at Wise Regional Health System and the North Texas Cancer Center will continue to offer exemplary services to Wise County and beyond with the very capable staff and support systems that we have.

The breast cancer program continued to grow with the ability to perform digital mammograms, stereotactic breast biopsies and breast MRIs. Dr. Candice Lovelace, a plastic surgeon, provided breast reconstruction surgeries, here in Decatur, without patients having to drive to the metroplex. Mary’s Gift, which provides mammograms to uninsured

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM

2


CANCER PROGRAM ACTIVITIES & ACHIEVEMENTS

T

he task of the Cancer Committee is to oversee the Cancer Program and to see that the program fulfills all aspects of a cancer program.

A. Quality Improvement Goals The cancer committee established goals for 2011 because its members believed that the achievement of these ends would lead to quality improvement for the cancer program and the people of Wise County. They include: 1. Continue to meet/exceed criteria for Commission on Cancer accreditation. 2. Continue to encourage all nurses to attend chemotherapy certification classes. 3. Offer PET/CT technology to the Wise County area. 4. Continue to increase awareness of treatment options available at the hospital and cancer center. 5. Improve patient support and prevention programs. 6. Conduct a site study on lymphoma cancer. Each of these goals have been successfully advanced or completed during 2010. B. Cancer Registry Progress The Cancer Registry at Wise Regional Health System was established January 1, 2007 and operates within the guidelines of the American College of Surgeons Commission on Cancer Approvals and Accreditation Program.

A total of 175 new cases were added for the year 2011. Of these cases, 156 were analytical and 19 were nonanalytical. This makes a total of 941 cases in the Registry database since the reference date of 2007. C. Monthly Tumor Conferences The monthly didactic tumor conferences have proven to be an important facet of interdisciplinary care at Wise Regional. The conferences are scheduled on the fourth Tuesday of each month from 12:30 to 1:30 and are regularly attended by physicians from medical oncology, radiation oncology, diagnostic radiology, pathology and surgery. Physicians from urology, family practice, pulmonology, hospitalists, as well as nurses and other allied health professionals also attend. The attendance by medical and nursing staff continues to grow and currently averages 20 attendees per meeting. The conferences are led by the Medical Director of Oncology, Dr. Neelima Maddukuri. Conference topics are determined by an identified patient’s and his/ her cancer site. A physician presents the patient’s history and physical findings and representatives from radiology and pathology review pertinent imaging studies and pathology slides. An open discussion includes AJCC stage, treatment options, national treatment guidelines, clinical trials (if applicable) and follow up.

The Cancer Registry, under the supervision of the Cancer Committee, is comprised of a computerized data center that includes a broad range of demographic, diagnostic, therapeutic and lifetime follow-up information about patients with cancer diagnosed and/ or treated at Wise Regional. In addition to meeting ACOS requirements, the intent of the registry is to encourage lifetime medical follow up of cancer patients and to provide a database for epidemiological, clinical, research and cancer program management. As the Cancer Registrar for Wise Regional, Mrs. Poehl is responsible for collecting accurate and complete data on all patients diagnosed and treated in our Cancer Program and for reporting it to the Texas Cancer Registry and to the National Cancer Database.

3

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM


Wise Regional participated in several community outreach events duri hospital sponsored a team for Relay For Life, benefiting the American The hospital participated in a community health fair at the Decatur Civ Cancer prevention and early detection information for breast, colon, an CANCER PROGRAM ACTIVITIES & ACHIEVEMENTS provided to attendees. Smoking cessation information was also provid rd In June, we held our 3 annual Survivors’ Day, a day that we celebrate survivorship over cancer. Survivors spoke about their experiences. The hospital sponsored a Men’s Health Fair at the hospital in October. During 2011, 10 tumor board conferences were being elevated. opportunity for men in our community to learn about cancer preventio conducted at which 35 patients with 21 cancer sites Also, in October, and stroke. The event included free PSA screening. 30 PSA’s were d were discussed. Some of the most frequent cancer Decatur hostedAlso, in October, Decatur sponsored “Paint the Town being elevated. sites (lung, colon, and ovarian, esophageal, CLL) “Paint theDecatur. Town Breast cancer survivors painted a stripe down Ma downtown were discussed at the conferences. Prospective Pink” in downtown cancer awareness information was handed out. presentation (before treatment decisions have been Decatur. Breast “Look Good, Feel Better®” support group in conjunction with the Am made) included 89% of the cases presented in 2011. cancer is survivors Society teaching women cancer patient’s beauty techniques to restor painted a stripe and self-image during cancer treatment. This group will meet quarterl D. Community Outreach down Main Center. “Reach to Recovery®” program is sponsored by the American In conjunction with the efforts of the cancer Street and help men andbreast women cope with breast cancer. The program has volun committee, members of the hospital staff of Wise cancer awareness breast cancer survivors who meet with the patient and family member Regional participated in several community outreach information opportunity to was express feelings, concerns, and ask questions of someon events during 2011. The hospital sponsored a team handed out. knowledgeable. There is an American Cancer Society Resource Room for Relay For Life, benefiting the American Cancer Women’s Health Center. In the Resource Room there are volunteers t Society. information to patients, family members, and caregivers along with an The hospital participated in a community health fair at the Decatur Civic Center in May. Cancer prevention and early detection information for breast, colon, and lung was provided to attendees. Smoking cessation information also was provided. In June, we held our 3rd annual Survivors’ Day, a day that celebrated our patient’s survivorship over cancer. Survivors spoke about their experiences. The hospital sponsored a Men’s Health Fair at the hospital in October. This was an opportunity for men in our community to learn about cancer prevention, heart disease and stroke. The event included free PSA screenings. Thirty PSA’s were drawn with four results

The 3rd annual Cancer Survivor Day was held at the Decatur Civic Center and featured several patient survivorship stories and a buffet lunch for cancer survivors, their families and caregivers.

PSA ng/ml 0.0-0.9 1.0-1.9 2.0-2.9 3.0-3.9 >=4.0 Total

<=59 2 2 1 3 8

PSA SCREENING AGE 60-69 70-79 6 3 3 3 1 2 1 13 6

>=80 1 1 1 3

Total 12 8 3 3 4 30

*********Senior Health Fair, Me Pink********** Wise Regional also hosted its Dazzle first Senior Health Fair in October specifically for adults over the age of 55. The fair offered free health screenings, blood draws, information about drug interactions, stroke awareness and cancer care available in the area. “Look Good, Feel Better®” support group in conjunction with the American Cancer Society is teaching women cancer patients beauty techniques to restore their appearance and self-image during cancer treatment. This group meets quarterly at the Cancer Center. “Reach to Recovery®” program is sponsored by the American Cancer Society to help men and women cope with breast cancer. The program has volunteers that are breast cancer survivors who meet with the patient and family member to give an opportunity to express feelings, concerns, and ask questions of someone who is knowledgeable.

Pictured to the left are the cancer survivors that were able to attend the lunch.

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM

4


M

WISE REGIONAL HEALTH FOUNDATION AND MARY’S GIFT

T

he Mary’s Gift Program at Wise Regional Health System provides free mammogram screenings to low-income, uninsured or underinsured women and men in Wise County.

In addition to traditional mammograms, the program offers expanded services, including: • Diagnostic Mammograms • Breast Ultrasounds • Sterotactic Biopsies • Post-Diagnosis Care All services are performed at the newly remodeled Wise Regional Women’s Health Center.

T

Da

he Dazzle Me Pink Fashion Show & Luncheon is held in April at the Decatur Civic Center. The sold-out event features door prizes, a live & silent auction and a runway-style event showcasing the latest styles for adults and children from local merchants.

v Pre

nt ion for A

e

T

me

Cancer

One hundred percent of the proceeds benefit Women’s Health Services for the underserved and the Mary’s Gift program.

z zl e

Pink

ty un Co LL Women of Wise

• Your $250. contribution will purchase a table and lunch for you and seven of your guests.

May we reserve your

table for our Fashion Show Luncheon on April 7th, 2010 12 noon • Decatur Civic Center The community response to this event has been amazing. The entire event has been underwritten and 100% of the proceeds will benefit Cancer Prevention for ALL Women of Wise County & Mary’s Gift. Join us with seven of your closest “girlfriends” for a time to remember!

he annual Paint the Town Pink event is held in October Local Fashions • Door Prizes • Silent Auction in conjunction with Breast Cancer Awareness month Call Wise Regional Health Foundation at on the Square in Decatur. The festive event encourages attendees to wear pink to recognize breast cancer 626-1384 before March 10th to RSVP. survivors and to honor those who have passed. To raise money, a bake sale and silent auction are held. A special pink line ceremony is conducted in which breast cancer survivors take turns painting a pink stripe down one of the main streets on the Square. Local businesses also assist in the awareness and fundraising by offering special promotions to their customers. All proceeds benefit Mary’s Gift and Women’s Services at Wise Regional, which provides mammograms and cervical cancer screenings to underserved women in Wise County.

5

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM


Seventy percent  of  the  newly  diagnosed  analytical  cases  live  in  Wise  County,  while  thirty  percent   live  in  surrounding  counties,  Parker,  Montague,  Young,  Jack,  and  Tarrant  Counties.     Seventy  percent  of  the  newly  diagnosed  analytical  cases  live  in  Wise  County,  while  thirty  percent   Seventy  percent  of  the  newly  diagnosed  analytical  cases  live  in  Wise  County,  while  thirty  percent  

NATIONAL CANCER DATABASE CANCER PATIENT PROFILE REPORTS (CP3R) live in  surrounding  counties,  Parker,  Montague,  Young,  Jack,  and  Tarrant  Counties.     live  in  surrounding  counties,  Parker,  Montague,  Young,  Jack,  and  Tarrant  Counties.     National Cancer Data Base Cancer Patient Profile Reports (CP3R)

National Cancer Data Base Cancer Patient Profile Reports (CP3R) National Cancer Base Cancer Patient Profile Reports (CP3R) The measures forData breast quality of care reported were developed by the CoC and he measures for breast quality of care reporting were developed by the CoC and harmonized with harmonized with measures developed through anwere independent but parallel process the The for quality of by CoC and Themeasures measures forbreast breast quality ofcare carereported reported weredeveloped developed bythe the CoC and Society for Clinical measures developed through an independent but parallel process with the American American Society for Clinical Oncology (ASCO) and the National Comprehensive harmonized with measures developed through but process the Oncology (ASCO) the National Comprehensive Cancer Network (NCCN). The three harmonized withand measures developed throughan anindependent independent butparallel parallel process the measures for Cancer Network (NCCN). The three measures for breast endorsed through the American Society for Clinical Oncology (ASCO) and the National Comprehensive breast quality of carefor reporting endorsed through thethe public/private partnership led by the National American Society Clinicalare Oncology (ASCO) and National Comprehensive public/private partnership led by the National Quality Forum (NQF). Cancer Cancer Network (NCCN). The measures for breast through the Quality Forum (NQF). The Cancer Program Practice Profile (CP3R) isthrough aThe web-based Cancer Network (NCCN). Thethree three measures forReports breastendorsed endorsed the reporting tool Program Practice Profile Reports (CP3R) is a web-based reporting tool that can used public/private partnership led by the National Quality Forum (NQF). The Cancer that can bepublic/private used by programs to empower administrators and(NQF). other staff workbecooperatively and partnership led byclinicians, the National Quality Forum The to Cancer by programs to empower clinicians, administrators and other staff to work cooperatively Program Practice Profile Reports (CP3R) is a web-based reporting tool that can be used collaboratively to identify problems in practice and delivery, and to implement best practices that will diminish Program Practice Profile Reports (CP3R) is a web-based reporting tool that can be used and collaboratively to identify problems in practice and delivery, andwork to implement best disparitiesby in programs care across Cancer Programs. 1 and to empower administrators by programs toCoC-Accredited empowerclinicians, clinicians, administrators andother otherstaff staffto to workcooperatively cooperatively1 practices that will diminish disparities inincare across CoC-Accredited Cancer Programs. and andcollaboratively collaborativelyto toidentify identifyproblems problems inpractice practiceand anddelivery, delivery,and andto toimplement implementbest best 1 • Radiation therapy is administered within 1 year (365 days) of diagnosis for practices that will diminish disparities in care across CoC-Accredited Cancer Programs. practices that will diminish disparities in care across CoC-Accredited Cancer Programs. 1 Radiation therapy is administered 1 year (365 days) of diagnosis for for women under age 70 receiving women under ageiswithin 70 receiving breast conserving surgery breast cancer. •• Radiation therapy administered within 11year days) for Radiation therapy administered within year(365 (365 days)of ofdiagnosis diagnosis for breast conserving surgery for breastiscancer. [BCS/RT] [BCS/RT] women womenunder under age age70 70receiving receivingbreast breastconserving conservingsurgery surgeryfor forbreast breastcancer. cancer. 2007 2008 2009 2010 [BCS/RT] [BCS/RT]

T

Wise Regional 100% (1 case) 2008 100% (1 case) 2009 100% (4 cases) 2010 100% (4 cases) 2007 2007 2008 2009 2010 State of Texas 68.1% 73.7% 76.5% 78.6%(4 cases) Wise Regional 100% (1 case) 100% (1 case) 100% (4 cases) 100% Wise Regional 100% (1 case) 100% (1 case) 100% (4 cases) 100% ACS Division (HITEX) 70.3% 75.7% 77.7% 80.0% (4 cases) State of Texas 68.1% 73.7% 76.5% 78.6% State of Texas 68.1% 73.7% 76.5% 78.6% Census Region(HITEX) (West) 74.5% 79.5% 80.9% 82.3% ACS Division 70.3% 75.7% 77.7% 80.0% ACS Division (HITEX) 70.3% 75.7% 77.7% 80.0% COC Program (CHCP) 85.2% 87.9% 88.6% 88.1% Census Region (West) 74.5% 79.5% 80.9% 82.3% Census Region (West) 74.5% 79.5% 80.9% 82.3% All COC approved programs 87.0% 88.9% 89.4% 89.1% COC 85.2% 87.9% 88.6% 88.1% COCProgram Program (CHCP) (CHCP) 85.2% 87.9% 88.6% 88.1% Combination chemotherapy is considered 88.9% or administered89.4% within 4 months (120 days) of All 89.1% AllCOC COCapproved approvedprograms programs 87.0% 87.0% 88.9% 89.4% 89.1%

diagnosis for chemotherapy women under is 70 with AJCCor T1cN0M0, or Stage II44ormonths III hormone receptor Combination administered within (120 of Combination chemotherapy isconsidered considered or administered within months (120days) days) of negative breast cancer. [MAC] diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor for women under 70 breast with AJCC T1cN0M0, III hormone receptor breast cancer. [MAC] 2007 or Stage II or2008 2009 negative 2010 negative [MAC] negative breastcancer. cancer. [MAC] Wise Regional StateRegional of Texas Wise Wise Regional(HITEX) ACS Division State of Texas State of Texas (West) Census Region ACS Division (HITEX) ACS Division (HITEX) COC Program (CHCP) Census Region (West) Census Region (West) All COC approved programs COC COCProgram Program (CHCP) (CHCP) All AllCOC COCapproved approvedprograms programs

100% (1 case) 2007 2007 80.6%(1 case) 100% 100% 81.2%(1 case) 80.6% 80.6% 82.2% 81.2% 81.2% 86.7% 82.2% 82.2% 88.1% 86.7% 86.7% 88.1% 88.1%

100% (1 case) 2008 2008 82.5%(1 case) 100% 100% 82.8%(1 case) 82.5% 82.5% 84.9% 82.8% 82.8% 89.3% 84.9% 84.9% 88.98% 89.3% 89.3% 88.98% 88.98%

100% (3 cases) 2009 2009 84.6%(3 cases) 100% 100% 85% (3 cases) 84.6% 84.6% 86.2% 85% 85% 90.2% 86.2% 86.2% 89.6% 90.2% 90.2% 89.6% 89.6%

100% (2 cases) 2010 2010 85.6%(2 cases) 100% 100% 85.7% (2 cases) 85.6% 85.6% 87.8% 85.7% 85.7% 90.6% 87.8% 87.8% 90.6% 90.6% 90.6% 90.6% 90.6%

• Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 of diagnosis for inhibitor women AJCC T1cor M0, or Stage •• Tamoxifen or generation aromatase isisconsidered administered Tamoxifen orthird thirddays) generation aromatase inhibitorwith considered orN0 administered Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of II or III11ERA and/or PRAof breast cancer. [HT] within year diagnosis for within year(365 (365days) days) ofpositive diagnosis forwomen womenwith withAJCC AJCCT1c T1cN0 N0M0, M0,or orStage Stage diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer. [HT] 2008cancer. [HT] 2009 2010 IIIIor PRA orIII IIIERA ERAand/or and/or2007 PRApositive positivebreast breast cancer. [HT] Wise Regional StateRegional of Texas Wise Wise Regional(HITEX) ACS Division State of Texas State of Texas (West) Census Region ACS Division (HITEX) ACS Division (HITEX) COC Program (CHCP) Census Region (West) Census Region (West) All COC approved programs COC COCProgram Program (CHCP) (CHCP) All AllCOC COCapproved approvedprograms programs

100% (2 cases) 2007 2007 61.0%(2 cases) 100% 100% 63.3% (2 cases) 61.0% 61.0% 65.4% 63.3% 63.3% 79.2% 65.4% 65.4% 81.0% 79.2% 79.2% 81.0% 81.0%

100% (2 cases) 2008 2008 67.3%(2 cases) 100% 100% 69.1%(2 cases) 67.3% 67.3% 70.1% 69.1% 69.1% 83.0% 70.1% 70.1% 83.8% 83.0% 83.0% 83.8% 83.8%

100% (8 cases) 2009 2009 70.7%(8 cases) 100% 100% 72.3% (8 cases) 70.7% 70.7% 73.5% 72.3% 72.3% 83.0% 73.5% 73.5% 84.9% 83.0% 83.0% 84.9% 84.9%

100% (13 cases) 2010 2010 76.2%(13 cases) 100% 100% 77.1% (13 cases) 76.2% 76.2% 78.1% 77.1% 77.1% 82.5% 78.1% 78.1% 84.9% 82.5% 82.5% 84.9% 84.9%

Wise Regional’s performance score for each year is significantly above those of other programs, and the cancer program is committed to ensure all patients are treated according to national standard guidelines.

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM

6


WISE REGIONAL PROGRAM DEVELOPMENT AND INTEGRATION WITH CANCER PROGRAM

T

his section highlights the Wise Regional Health System and allied programs that directly interrelate with patients who have malignancy.

A. Dietary Truly Texas Room Service patient meal system has been in place for several years. The system has been extremely successful as evidenced by our excellent patient satisfaction scores and very positive patient comments. It is a definite plus for our cancer patients (especially those receiving chemotherapy) since it allows the patient to order whatever they want – whenever they want it. The flexibility is especially advantageous to those patients trying to function around periods of nausea and/or no appetite. The room service ambassadors will gently encourage patients to choose some type of food, drink or supplement during the day and will gladly make suggestions if requested. Our registered dietitian is available to work with patients who are experiencing difficulty in managing their meals. It is always our goal to help the patient meet their nutritional needs in a way that is most satisfactory to them. B. Inpatient Oncology The nursing staff at Wise Regional has seen a dramatic shift in the overall oncology experience through patient care initiatives as the number of oncology admissions continues to grow. The nurses take an active role in learning about chemotherapy practices and cancer education. The nurses who care for oncology patients are required to attend a two-day chemotherapy/ biotherapy course sponsored by the Oncology Nursing Society. The course teaches the guidelines and recommendations for practice and emphasizes both the education aspects of oncology, and the clinical aspects of chemotherapy and biotherapy administration and patient care. Wise Regional currently employs five registered nurses who are certified to administer chemotherapy. In-service training and education presentations are offered on a regular basis and an annual competency test is conducted to keep each nurse current on the latest in cancer education. These additional measures foster a climate of continuing education resulting in the hospital’s nursing staff providing excellent care to our patients.

7

C. Palliative Care The hospital is working to develop a palliative care program. This program is designed to be an integrated part of the patient’s care plan. This program does not replace the patient’s primary treatment but works together to treat discomfort and stress of cancer. D. Pathology and Laboratory Medicine The Pathology and Laboratory Medicine Department is staffed on-site by board-certified pathologists including pathologists board-certified in hematopatholgy and gastrointestinal pathology. The pathologists help provide diagnostic, prognostic and predictive information utilizing advanced technology to determine the appropriate course of treatment. E. Pharmacy Pharmacy Services is supported by four full-time PharmD Pharmacists that are dedicated to improving the care of cancer patients and their quality of life. Chemotherapy is prepared on-site in the pharmacy and is delivered to the hospital floor to be administered to our inpatients by oncology trained nurses. The outpatient pharmacy is staffed by one full-time PharmD Pharmacist and one full-time RN, both which have received specialized training in chemotherapy preparation and administration. F. Radiation Therapy In radiation therapy, two advanced techniques are used: Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT). IMRT has been used since the opening of the Cancer Center and offers a precise means of delivering high radiation doses to a smaller target area, sparing surrounding healthy tissue. IGRT double checks the field accuracy to ensure precise and accurate delivery of the radiation dose to the cancer target. PET/CT is used to provide more comprehensive treatment planning. These techniques have been shown to provide greater benefits to patients by improving recovery time and reducing side effects and complications associated with conventional radiation therapy treatments. G. Radiology In July, Wise Regional began offering PET/CT technology through a contract with a mobile unit. It is the only service of its kind available in Wise County. Previously, patients had to travel to the metroplex.

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM


WISE REGIONAL PROGRAM DEVELOPMENT AND INTEGRATION WITH CANCER PROGRAM The PET/CT technology combines images of cellular metabolic activity from a PET scan with the anatomical references from a CT exam into one image, allowing physicians to view metabolic changes in the proper anatomical context of the body. This helps physicians diagnose a problem and predict the likely outcome of various therapeutic alternatives, pinpoint the best approach to treatment and monitor progress. The PET/CT technology is the same caliber of machine used at MD Cancer Center in Houston. By using this technology, physicians at Wise Regional are able to get a more accurate diagnosis and able to provide a better assessment, allowing for a better chance for successful treatment. H. Rehabilitation Unit Rehabilitation focuses on improving independence in self-care tasks by increasing strength and endurance through compensatory techniques and training in the use of adaptive equipment. This allows the patients more days of increased independence and dignity because they did not have to ask for help with every little day-to-day activity such as brushing their teeth, eating, bathing and toileting. The lymphedema program at Wise Regional is available to breast cancer patients, upon request. I. Social Services The Department of Social Services/Case Management follows closely the patients diagnosed and treated in the hospital and cancer treatment center and provide:

• guidance in applying for financial assistance and act as a liaison or advocate for the patient and the financial office. • assistance and help identify pharmaceutical patient assistance programs which may be able to reimburse/replace or provide medications at discounted cost to those patients that qualify. • face-to-face interviews with the patients in order to identify other needs or support that might help in the over all treatment of our patients. • support for our patient’s spiritual needs as appropriate. • locate programs that are diagnosis specific that may help with unique needs to the individual patient. • connect the patient with appropriate referrals for services in-home, in a long-term care facility or in a hospital setting J. Surgery The surgery department performs inpatient and outpatient surgical procedures in many surgical specialties: orthopedics, urology, general surgery, gynecology, ENT, ophthalmology, cardiac, thoracic, spine, vascular, plastic surgery, bariatrics, podiatry and gastrointestinal endoscopy. The OR has advanced equipment for minimally invasive surgical procedures. The perioperative services staff are highly skilled and are encouraged and supported to participate in continuing education programs. The department includes Assessment, Pre-Op Holding, Surgery and the Post Anesthesia Care Unit so that we can ensure continuity of care for our patients.

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM

8


COMMISSION ON CANCER ACCREDITATION AND CANCER RESOURCE ROOM

I

n 2010, the American College of Surgeons Commission on Cancer recognized Wise Regional Health System’s Oncology Program with a threeyear accreditation with commendations for its commitment to establishing high quality treatment programs and its multidisciplinary approach to treating cancer patients. The three-year accreditation with commendations is the CoC’s highest level of accreditation. It is awarded when a health organization complies with all 36 commission standards. The CoC makes its decisions on whether to grant accreditation to a health organization based on five criteria: • Clinical services provide advanced pre-treatment evaluation, staging, treatment and clinical followup for cancer patients seen at the facility. • The organization’s cancer committee leads the program by setting goals, monitoring activity, evaluating patient outcomes and improving care. • Cancer conferences (or Multi-Disciplinary Team meetings) provide a forum for patient consultation and contribute to physician education. • The quality improvement program provides the forum to evaluate and improve patient outcomes. • The cancer registry and database is the basis for monitoring the quality of care. The CoC, established in 1922, strives to reduce the morbidity and mortality of cancer through education; sets cancer care standards; and monitors quality care. In the 1930s, the commission established standards, a review program and cancer program accreditation. The commission continues to promote and support multidisciplinary care and overall quality improvements through its standards.

9

The American Cancer Society Resource Room at Wise Regional is staffed by hospital volunteers trained by the American Cancer Society. They offer patients, families and caregivers information about cancer, along with an empathetic ear. The Cancer Resource Room also offers a complimentary selection of wigs, hats and other accessories. Patients are welcomed to try them on and select items that make them feel more confident about their appearance.

Telegenetics - Coming in 2012! Planning is underway for Wise Regional Health System to be one of the first hospitals in North Texas equipped with the latest in technology with the addition of a telemedicine clinic for cancer genetic counseling. Telemedicine is the ability for patients in rural areas and health care providers in larger cities to communicate electronically, via video conference, providing for real-time interaction, allowing access to medical services not typically available in rural communities. Patients who have strong family history of cancer, those with birth defects, genetic disorders or other factors that put them at high risk for various cancers will be able to conference one-on-one with a genetic counselor from UT Southwestern to identify and predict their risk of developing cancer and if further testing or screening is recommended.

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM


CANCER REGISTRY REPORT

T

he Cancer Registry is an important part of the Cancer Program at Wise Regional Health System. The Cancer Registry, under the supervision of the Cancer Committee, collects and documents demographic information, pathological and diagnostic testing results, treatment information and follow up data. This Registry follows the guidelines of the American College of Surgeons Commission on Cancer. The Cancer Committee reviews the data annually for accuracy, timeliness and quality.

In 2011, Wise Regional diagnosed and treated 156 newly diagnosed cancer cases (analytical). Nineteen cancer cases were recurrent cancers. This brings the total of cases in Cancer Registry database to 941 cases. Out of the 156 analytical cancer cases, females accounted for 52% (81 cases) and males accounted for 48% (75 cases). The median age was 60-69 for females and median age for males was 70-79. Seventy percent of the newly diagnosed analytical cases live in Wise County, while thirty percent live in surrounding counties, Parker, Montague, Young, Jack, and Tarrant Counties.

2011 MOST COMMON CASE SITES

PRIMARY SITE TABULATION FOR ALL 2011 CANCER CASES Primary Site

Primary Site WRHS

Class

Total

TX

Natâ&#x20AC;&#x2122;l

Analytical

Non-Analytical

Breast

21

15,070 232,620

6

5

1

Lung

25

13,080 221,130

Digestive System

40

39

1

Prostate

9

12,960 240,890

Respiratory System

31

29

2

Colo/Rectal

25

9,550

141,210

Blood & Bone Marrow

22

19

3

Bladder

11

3,670

69,250

Connect/Soft Tissue

1

1

0

Skin

6

5

1

Breast

24

21

3

Female Genital

4

3

1

Male Genital

13

10

3

Urinary System

16

14

2

Brain & CNS

1

0

1

Endocrine

2

2

0

Lymphatic System

5

5

0

Unknown Primary

4

3

1

175

156

19

Oral Cavity

All Sites

*National Comparison and American Society Fact & Figures 2011

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM

10


FOCUSED COLON CANCER CANCER FINDINGS REPORT

C

olorectal carcinoma (CRC) is the third most common cancer diagnosed among men and women in the United States and the second leading cause of death from cancer. Annually approximately 143,460 new cases of large bowel cancer are diagnosed, of which 103,170 are colon and the remainder rectal cancers. Approximately 51,690 Americans die of CRC, each year, accounting for approximately 9 percent of all cancer deaths. Although CRC mortality has been progressively declining since 1990 at a rate of about 3 percent per year, (largely due to reduced exposure to risk factors, routine screening of individuals at increased risk for CRC, prevention through polypectomies and improved treatment after diagnosis) it still remains the second most common cause of cancer death in the US. CLINICAL MANIFESTATIONS: CRC can present with abdominal pain, blood in the stool, rectal bleeding and/or change in bowel habits. Both constipation and diarrhea can be the earliest symptoms of CRC as well as fatigue and weakness due to anemia from blood loss.

RISK/PROTECTIVE FACTORS: Various risk factors for CRC include family history of CRC in a first degree relative less than 50 years of age or in two or more first degree relatives at any age, prior patient history of colon polyps (tubular adenomas) or including Crohn’s CRCchronic can presentinflammatory with abdominal pain,bowel blood in diseases the stool, rectal bleeding and/or change in CRC can present with abdominal bloodcan in the stool, rectal bleeding and/or change in as bowel habits. Both constipation and pain, diarrhea be the earliest symptoms of CRC as well Disease and Ulcerative Colitis. Other potential risk bowel Both due constipation andfrom diarrhea be the earliest symptoms of CRC as well as fatigue andhabits. weakness to anemia bloodcan loss. fatigue andinclude weakness due to anemia from blood (high loss. factors dietary factors fat and/or low factors Risk/Protective fiber diets, high calorie diets, high meat protein diets), factors Risk/Protective smoking, alcohol consumption, radiation tothan Various risk factorshigh for CRC include family history of CRC in prior a first degree relative less Various risk factors for CRC include family history of CRC in a first degree relative less than 50 years of age or inortwo or more first degree relatives at any age, prior patient historyofof 50 years of ageand in two or more first degree genetic relatives at any age, priorsuch patient history abdomen miscellaneous factors, as coloncolon polyps (tubular adenomas) or chronic inflammatory Crohn’s polyps (tubular adenomas) or chronic inflammatorybowel boweldiseases diseases including including Crohn’s Familial Adenomatous Polyposis (FAP) and Hereditary Disease and and Ulcerative Colitis. Other potential risk include dietary factors (highfat fat Disease Ulcerative Colitis. Other potential riskfactors factors include dietary factors (high and/or low fiber diets, highhigh calorie diets, high meat diets), high alcohol alcohol and/or low fiber diets, calorie diets, high meatprotein protein diets),smoking, smoking, high Non-Polyposis Colorectal Cancer (HNPCC). consumption, priorprior radiation to abdomen and miscellaneous Familial consumption, radiation to abdomen and miscellaneousgenetic genetic factors factors Familial Adenomatous Polyposis (FAP) andand Hereditary Non-Polyposis (HNPCC). Adenomatous Polyposis (FAP) Hereditary Non-PolyposisColorectal Colorectal Cancer Cancer (HNPCC).

Male vs. Female patients with colorectal cancer at Wise Regional Health System 2007-2011

Age Groupings of Colorectal Cancer at Wise Regional Health System 2007-2011 substantial body of evidence supports a protective effect of aspirin and other AAnonsteroidal substantial body of evidence supports a protective antiinflammatory drugs on the development of colonic adenomas and cancer. of A potential protective diet includes avoidance of processed effect aspirin and other nonsteroidal anti- and charred red meat, inclusion of vegetables (especially cruciferous), an adequate amount of intake of inflammatory onlimited the caloric development of colonic folate from food, highdrugs fiber diet, intake, and avoidance of excessive alcohol. Modifiable factors including obesity and lack of physical activity have been adenomas andrisk cancer. A potential protective diet consistently identified in observational studies. includes avoidance of processed and charred red meat, inclusion of vegetables (especially cruciferous), an adequate amount of intake of folate from food, highfiber diet, limited caloric intake, and avoidance of excessive alcohol. Modifiable risk factors including obesity and lack of physical activity have been consistently identified in observational studies.

DIAGNOSTIC/SCREENING TESTS: Today there is a range of options for CRC screening in the average risk population. These include stool occult blood tests, digital rectal examination (DRE), flexible sigmoidoscopy (FSIG), colonoscopy, double-contrast barium enema (DCBE) and computed tomographic colonography (CTC). STAGING: The stage of a colon cancer has three components, Diagnostic/Screening tests status of the regional nodes primary tumor (T), Today and there isdistant a range of options for CRC screening the average risk population. These (N), metastasis (M),inwhich together are include stool occult blood tests, digital rectal examination (DRE), flexible sigmoidoscopy combined to form stage groupings, from I to IV. Stage (FSIG), colonoscopy, double-contrast barium enema (DCBE) and computed tomographic colonography (CTC). groupings permit the stratification of prognosis, Staging is useful for the selection of treatment. Various which The stage of a colon cancer has three components, primary tumor (T), status of the radiological used in metastatic workup include regional nodes (N),tests and distant metastasis (M), which together are combined to formCT stage groupings, from I to IV. Stage groupings permit the stratification of prognosis, scans, Liver MRI, PET/CT and bone scans. which is useful for the selection of treatment. Various radiological tests used in metastatic workup include CT scans, Liver MRI, PET/CT and bone scans

Male colorectal cancer canceratatWise WiseRegional RegionalHealth HealthSystem System 2007-2011 Malevs. vs.Female Female patients patients with with colorectal 2007-2011

Male vs. Female patients with colorectal cancer at Wise Regional Health System 2007-2011

Stage Distributionofofpatients patients at Wise Regional Health System in the past 5 years Stage Distribution at Wise Regional Health System in the past 5 years

Treatment

Treatment options for colorectal cancer include a multimodality approach using surgery chemotherapy (neo adjuvant vs adjuvant) and radiation therapy, tailored individually depending upon their presentation. Wise Regional Cases vs Community Hospitals in Texas

11

Treatment

Wise

Texas 2007

Wise 2011

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE2007REGIONAL HEALTH SYSTEM Surgery Only

Surgery and Chemotherapy Surgery, Radiation, and

7

586

10

4

238

9

0

85

2


FOCUSED COLON CANCER CANCER FINDINGS REPORT TREATMENT: prognosis, stage for stage, than those with lower levels. Treatment options for colorectal cancer include Furthermore, elevated preoperative CEA levels that do Stage Distribution of patients at Wise Regional Health System in the past 5 years a Treatment multimodality approach using surgery not normalize following surgical resection imply the chemotherapy (neo adjuvant vs adjuvant) and radiation presence of persistent disease and the need for further Treatment options for colorectal cancer include a multimodality approach using surgery therapy, tailored individually depending upon their evaluation. chemotherapy (neo adjuvant vs adjuvant) and radiation therapy, tailored individually depending upon their presentation. presentation. PROGNOSIS: Wise Regional Cases vs Community Hospitals in Texas Five-year survival rates according to tumor stage Treatment Wise 2007 Texas 2007 Wise 2011 at diagnosis using the older 2002 AJCC staging for Surgery Only 7 586 10 colon cancer reported to the SEER (Surveillance, Surgery and Chemotherapy 4 238 9 Epidemiology and End Results) database between 1991 Surgery, Radiation, and Chemotherapy 0 85 2 and 2000 were as follows: • Stage I (T1-2 N0) — 93 percent Radiation and Chemotherapy 1 24 2 • Stage IIA (T3N0) — 85 percent Other 0 99 0 • Stage IIB (T4N0) — 72 percent No treatment 0 147 2 • Stage IIIA (T1-2 N1) — 83 percent Total 12 1179 25 • Stage IIIB (T3-4 N1) — 64 percent NCDB • Stage IIIC (N2 disease) — 44 percent Tumor markers TUMOR MARKERS: A variety of serum markers have been associated with SURVEILLANCE: CRC, particularly carcinoembryonic antigen (CEA), Following treatment for stage I colorectal cancer, postand carbohydrate antigen (CA) 19-9. However, these treatment surveillance consists of periodic history, markers have a low diagnostic ability to detect primary physical examination and colonoscopy. CRC due to significant overlap with benign disease and Following treatment for a stage II or III colon cancer, low sensitivity for early stage disease. post-treatment surveillance usually consists of periodic American Society of Clinical Oncology (ASCO) history and physical examination, assay of the serum recommends that serum CEA nor CA 19-9 levels CEA, annual surveillance CT scans, and periodic not be used as a screening test for colorectal cancer. colonoscopy. However, serum levels of CEA do have prognostic utility in patients with newly diagnosed CRC. Patients with preoperative serum CEA >5 ng/mL have a worse

*From COC NCDB

Surveillance

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM Following treatment for stage I colorectal cancer, posttreatment surveillance consists of periodic history, physical examination and colonoscopy.

12


GLOSSARY

CEA: Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth. CEA elevation is known to be affected by multiple factors. Stool Occult Blood Test: A stool test is one of many tests used to look for colorectal cancer. These tests may find cancer early and help determine which treatment works better. Digital Rectal Examination: During a digital rectal examination, a physician inserts a finger into the rectum to check for problems with organs or other structures in the pelvis and lower abdomen. This exam is often part of a routine prostate exam. Flexible Sigmoidoscopy: A flexible sigmoidoscopy is an outpatient procedure used to evaluate gastrointestinal symptoms. This procedure is used to screen people older than 50 for colon and rectal cancer. Colonoscopy: A colonoscopy is a procedure used to examine the large bowel (colon and rectum). A colonoscopy is used to screen for colon cancer. Double-Contrast Barium Enema: A double-contrast barium enema is an X-ray examination of the large intestine (color and rectum). During the test the colon is filled with barium to allow for a more detailed view of the inner surface of the colon. Computed Tomographic Colongraphy: Also known as a virtual colonoscopy, this procedure uses X-ray technology and computers to take 2D or 3D images of the interior lining of your large intestine to screen for precancerous and cancerous growths.

13

2012 ANNUAL REPORT OF THE CANCER PROGRAM AT WISE REGIONAL HEALTH SYSTEM


Affiliated with, but not controlled by, Baylor Health Care System or its subsidiaries or community medical centers

CANCER COMMITTEE

Direct inquiries about this report to: Wise Regional Health System Cancer Program 609 Medical Center Drive Decatur, Texas 76234 Telephone: 940-626-2300 Fax: 940-626-1281 www.WiseRegional.com For additional services, contact: Wise Regional Health System 940-627-5921 Wise Regional Health Foundation 940-626-1384 Customer Service 940-626-1240 Marketing and Communications 940-626-2786 NCI Cancer Information Service 1-800-4-CANCER American Cancer Society 1-800-227-2345 www.cancer.org

The 2012 Annual Report of the Cancer Program was published by Wise Regional Health System for patients, donors, and friends of Wise Regional Health System. All contents Š2012 Wise Regional Health System. Contents may be reproduced by permission from the editor and if appropriate credit is given.


Cancer Care and Treatment in Wise and Surrounding Counties The North Texas Cancer Center at Wise Regional Health System provides our communities with the latest technologies in cancer treatment. Cancer patients who live in this area now have an opportunity to seek treatment close to home rather than traveling to a facility in the Metroplex. The radiation oncology program offers intensity modulated radiation therapy (IMRT), which enhances radiation treatment planning for the patient and allows delivery of high doses of radiation to a tumor while minimizing the amount of radiation to normal tissues. The medical oncology program has medical oncologists and oncology-trained staff who offer clinical trial drug programs and the latest chemotherapy agents using chemotherapy infusion chairs. The oncology groups of both programs play a major role in cancer care to include management of treatment plans, therapies, and evaluations of the patient’s progress.

Prepared and distributed by:

Affiliated with, but not controlled by, Baylor Health Care System or its subsidiaries or community medical centers

609 Medical Center Drive • Decatur, TX • 76234 940.627.5921 • WiseRegional.com

2012 Cancer Program Annual Report  
Read more
Read more
Similar to
Popular now
Just for you